Changeflow GovPing Pharma & Drug Safety Immunotherapy Cell Patent - Memorial Sloan Kett...
Routine Notice Added Final

Immunotherapy Cell Patent - Memorial Sloan Kettering

Favicon for changeflow.com ChangeBridge: EPO Bulletin - Biotech (C12N)
Published March 25th, 2026
Detected April 1st, 2026
Email

Summary

The European Patent Office published patent application EP4007586A1 for Memorial Sloan Kettering Cancer Center, covering cells for improved immunotherapy and their uses. The patent designates multiple European states including DE, FR, GB, IT, NL, and others. This is a routine patent publication notice for a cancer immunotherapy technology developed by David A. Scheinberg and Leila Peraro.

What changed

The EPO published patent EP4007586A1 (filed as EP4007586) for Memorial Sloan Kettering Cancer Center and affiliated institutions, covering immunotherapy cells and therapeutic uses thereof. The application includes IPC classifications spanning cell therapy (C12N 5/0783), antibodies (C07K 16/28), and related pharmaceutical compositions. The designated contracting states include all major European jurisdictions.

Patent publication notices do not impose compliance obligations. Entities conducting immunotherapy research or developing CAR-T or related cell therapies should review the patent claims to assess potential freedom-to-operate implications in the European market. No action is required based solely on this publication.

What to do next

  1. Review patent claims EP4007586A1 to assess freedom to operate in European immunotherapy markets
  2. Monitor EPO register for any opposition period following formal grant

Source document (simplified)

← EPO Patent Bulletin

CELLS FOR IMPROVED IMMUNOTHERAPY AND USES THEREOF

Publication EP4007586A1 Kind: A1 Mar 25, 2026

Applicants

Memorial Sloan Kettering Cancer Center, Sloan-Kettering Institute for
Cancer Research, Memorial Hospital for Cancer and Allied
Diseases

Inventors

SCHEINBERG, David, A., PERARO, Leila

IPC Classifications

A61K 35/15 20150101AFI20230816BHEP A61K 35/17 20150101ALI20230816BHEP A61K 38/43 20060101ALI20230816BHEP A61K 38/46 20060101ALI20230816BHEP C07K 14/725 20060101ALI20230816BHEP C07K 16/28 20060101ALI20230816BHEP A61K 38/00 20060101ALI20230816BHEP A61K 39/00 20060101ALI20230816BHEP C12N 5/0783 20100101ALI20230816BHEP C12N 9/64 20060101ALI20230816BHEP

Designated States

AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR

View original document →

Named provisions

CELLS FOR IMPROVED IMMUNOTHERAPY AND USES THEREOF

Source

Analysis generated by AI. Source diff and links are from the original.

Classification

Agency
EPO
Published
March 25th, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Final
Change scope
Minor
Document ID
EP4007586A1

Who this affects

Applies to
Healthcare providers Pharmaceutical companies Clinical investigators
Industry sector
3254 Pharmaceutical Manufacturing 6211 Healthcare Providers 3254.1 Biotechnology
Activity scope
Biotechnology Pharmaceutical Patents Cell Therapy
Geographic scope
European Union EU

Taxonomy

Primary area
Healthcare
Operational domain
Intellectual Property
Topics
Pharmaceuticals Intellectual Property

Get Pharma & Drug Safety alerts

Weekly digest. AI-summarized, no noise.

Free. Unsubscribe anytime.

Get alerts for this source

We'll email you when ChangeBridge: EPO Bulletin - Biotech (C12N) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.